Abstract:Purpose/Objective(s) programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still unsatisfactory. Basic studies have already confirmed PD-1 inhibitors had concurrent synergistic effect with chemotherapy and radiotherapy. Few studies concerned about the treatment pattern for concurrent PD-1 inhibitors combination with chemoradiation for R/M NPC. There was still much uncertainty about the timing, fraction dose and total dose for PD-1 inhibitors combination with radiation. Therefore, we aimed to explore the substantial effect and toxicity of this new pattern for R/M NPC. Materials/Methods We prospectively enrolled 42 R/M NPC patients from August 2018 to May 2021 in out institution. All the patients received concurrent PD-1 inhibitor combination with chemoradiation, and followed with maintenance of PD-1 inhibitors, and we analyzed PD-L1 expression by 22C3 kit. Objective response rate (ORR) and disease control rate (DCR) were calculated by irRECIST 1.1. CTCAE-5.0 was used to evaluate the toxicity and Kaplan-Meier method was used to analyze survival rate. Results The median age was 48 years old (range 25-81), the median follow up time was 16.5 months (range 2-62). Nine patients had recurrent disease, 33 patients had metastatic disease, and 3 patients had both recurrence and metastasis disease. The median numbers of metastatic sites were 3 (range 1-7), and the most common metastatic sites were lung and liver. All the recurrent and measurable metastatic lesions were treated with radiotherapy. 9 recurrent patients received a median radiation dose of 60Gy. The measurable metastatic lesions received a median radiation dose of 54Gy. The median cycles of cisplatin-based chemotherapy were 5. Median time of PD-1 inhibitor was 9.5 months. At 3 months after the completion of chemoradiation, ORR and DCR were 90.5% and 100% respectively. The median PFS was 18 months, with 6 and 12 months PFS rates were 90.2% and 70.7%. 1 and 2-years OS rates were 94.6% and 86.2%, and the median OS had not reached. For the PD-L1 expression, 24 patients were positive, 18 were negative. The median PFS was 20.7 and 16.5 months for positive and negative group, respectively (p=0.01). Most common G3-4 toxicities were leucopenia (45.2%), anemia (38.1%), anorexia (7.1%), and fatigue (7.1%). There was no G3-4 toxicity for pneumonia, and no G5 toxicity was observed. Conclusion This new treatment pattern of concurrent PD-1 inhibitors combination with chemoradiation shows a promising efficacy and tolerable toxicity for R/M NPC. The patients with positive PD-L1 expression had better survival outcome than negative group. Keywords: PD-1 inhibitors, concurrent, recurrent, metastatic, nasopharyngeal carcinoma, chemoradiation

PD-1 and PD-L1 Expression in 132 Recurrent Nasopharyngeal Carcinoma: the Correlation with Anemia and Outcomes.

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

Co-expression of PD-1 and PD-L1 Predicts Poor Outcome in Nasopharyngeal Carcinoma

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma

Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma

PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial

PD-1 High Expression Predicts Lower Local Disease Control in Stage IV M0 Nasopharyngeal Carcinoma

High PD-L1 Expression Predicts Metastasis in Nasopharyngeal Carcinoma

PD-L1 Associated with the Expression of Cancer Cell-Intrinsic PD-1 and P-S6 Proteins and Predicted a Good Prognosis in Nasopharyngeal Carcinoma

PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials

Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer

Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.

The Prognostic Significance of PD-L1 and PD-1 Expression in Patients with Nasopharyngeal Carcinoma: a Systematic Review and Meta-Analysis.

Expression and Clinical Significance of Programmed Death Ligand 1 in Nasopharyngeal Carcinoma.

Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment

Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma

Preliminary Analysis of Concurrent Programmed Cell Death-1 Inhibitor Combination with Chemoradiation for Recurrent/Metastatic Nasopharyngeal Carcinoma Patients: A Phase II Study

Co-expression of AFAP1-AS1 and PD-1 Predicts Poor Prognosis in Nasopharyngeal Carcinoma

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients

Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) in Patients with Refractory/metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label Phase II Clinical Study